Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

Cancer Control

Volumn 9, Issue 2, 2002, Pages 99-105

  Aksentijevich, Ivan ^a   Flinn, Ian W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

EID: 0036242536     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900202     Document Type: Article

References (27)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
3. Monoclonal anti-body1F5 (anti-CD20) serotherapy of human B cell lymphomas
4. The interaction of murine IgG subclass proteins with human monocyte Fc receptors
5. Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
6. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
7. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
8. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
9. In vivo "purging" of residual disease in CLL with Campath-1H
10. The CAMPATH-1 antigen (CDw52)
11. Consolidative immunotherapy with Rituxan in autologous stem cell transplants for follicular lymphoma is associated with molecular remissions
12. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
13. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
14. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays
15. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
16. Rituximab following high dose chemotherapy and autografting in B-cell non-Hodgkin's lymphoma (NHL): Preliminary results of a phase I-II trial
17. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab
18. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins
19. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
20. Radioimunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
21. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
22. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
23. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
24. Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): Synergistic results with no added toxicity
25. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01
26. 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL
27. Yttrium 90-labeled antfferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease